Alembic Pharmaceuticals Limited · NSE:APLLTD

Alembic Pharmaceuticals — Investor Presentation (June 2020)

13 slides from Alembic Pharmaceuticals's investor presentation, June 2020

  1. Slide 1: Alembic Pharmaceuticals Limited Investor presentation – June 2020

    Alembic Pharmaceuticals Limited Investor presentation – June 2020 BSE & NSE: APLLTD

  2. Slide 2: Milestones

    Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2010 Pharmaceuticals business demerged from Alembic – APL listed 2012 Formed a JV, Rhizen, for NCE research Launched fir

  3. Slide 3: Financial Highlights

    Financial Highlights INR Bn Particulars Q1 FY21 Q1 FY20 Growth YTD FY20 Net Sales 13.41 9.49 41% 46.06 EBIDTA Pre R&D 5.49 3.31 66% 18.15 Margin % 41% 35% 39% R&D 1.41 1.39 2% 6.45 R&D % 11% 15% 14% EBIDTA Post R&D 4.16 2.00 108% 12.13 Margin % 31% 21% 26% Net Profit 3.01 1.24 144% 8.29 Capex 1.42 1

  4. Slide 4: Business snapshot – Q1FY21

    Business snapshot – Q1FY21 Formulations Generics Branded API Total US Ex‐US India Revenue Q1FY21 (INR Bn) 5.96 1.75 3.06 2.64 13.41 API Vet 20% 20% 3% Q1FY21 Revenue 44% Generics Acute 57% Contribution 6% Branded 23% 13% Speciality 14% Growth Q1FY21 ‐6% 73% 62% 54% 41% over Q1FY20 Growth Q1FY21 ‐11%

  5. Slide 5: US Generic

    US Generic INR Bn Revenue – Q1 FY21 INR Bn Revenue – Last 4 Years CAGR ‐ 29% 19.76 5.96 12.88 3.45 9.19 9.20 Q1FY20 Q1FY21 FY17 FY18 FY19 FY20 Approved ANDAs Derma  Well‐established US front end having strong customer base 10 Ophthalmic 12  Expanded our capabilities to deliver a diverse portfolio

  6. Slide 6: Ex-US Generics

    Ex‐US Generics Revenue : Q1 FY21 INR Bn Revenue – Last 4 Years INR Bn 1.75 CAGR ‐ 16% 1.08 4.94 4.97 Q1FY20 Q1FY21 3.20  Ex‐US driven by partnership 2.86  Presence in following markets ‐ Europe, Canada, Australia, Brazil and South Africa  The business will focus on new launches across key markets

  7. Slide 7: API

    API Revenue : Q1 FY21 INR Bn Revenue – Last 4 Years INR Bn 2.64 CAGR ‐ 3% 1.72 7.71 7.08 6.40 6.51 Q1FY20 Q1FY21  Sales across geographies as preferred supplier  Investing in plants to create additional capacities  FDA Compliant plants  State of the art R&D center and Process development lab  1

  8. Slide 8: R&D: Significant investments in building capabilities

    R&D Significant 10.0 investments in building capabilities INR Bn ANDA – Accelerated filings & approvals 37* 8.0 Filing 13.7% 14.0% 13.1% 12.7% 29 30 Approval 6.0 25 10.1% R&D Spend 20 19 18* * 11 Filings & 4.0 7 Approvals 6.5 R&D % of 10 were 5.0 sales 2.0 4.3 4.1 8 contributed by 3.2 5 acquisition

  9. Slide 9: State of the art facilities and infrastructure

    State of the art facilities and infrastructure Audit/Filing Location Dosage Form status International Generics F1 – Panelav General Oral Solids Mar’20* Oncology Oral Solids Jun’19* F2 – Panelav Oncology Injectables H2FY21# F2 ‐ Panelav F3 ‐ Karkhadi General Injectables F3 – Karkhadi Ophthalmic Jan’2

  10. Slide 10: Branded Business

    Branded Business Revenue – Q4 FY20 INR Bn Revenue – Last 4 Years CAGR ‐ 4% INR Bn 13.8 14.3 3.24 12.5 12.7 Vet 3.06 0.38 0.36 Acute 0.90 0.87 Speciality Linear (Total) 1.97 1.83 Q1FY20 Q1FY21 FY17 FY18 FY19 FY20 Marketing organization Key achievements  5000 + Marketing team  3 Brands in top 300 

  11. Slide 11: Therapy-wise Performance Q1 FY21

    Therapy‐wise Performance Q1 FY21 Q1 FY21 Q1 FY20 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy (%) Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 12 2.1 11 19 12 2.1 8 1 Gynecology ‐11 2.7 ‐17

  12. Slide 12: Financials: Generating consistent returns

    Financials : Generating consistent returns Revenue INR Bn EBIDTA Net Profit INR Bn 46.06 INR Bn 12.13 39.35 8.29 31.34 31.31 8.75 5.84 6.15 6.42 4.03 4.13 FY17 FY18 FY19 FY20 FY17 FY18 FY19 FY20 FY17 FY18 FY19 FY20 CAGR ‐ 14% CAGR ‐ 25% CAGR ‐ 27% EBIDTA margin % Capex ROCE % INR Bn 26 32* 6.97 30*

  13. Slide 13: Thank you

    Thank you Safe Harbour Agreement: Materials and information provided during this presentation may contain ‘forward‐looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and resu

Alembic Pharmaceuticals — Investor Presentation (June 2020) on 6ix